Baxter Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 2,000.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 0.57 M
as on 16-11-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 1,130.21 Cr
as on 16-11-2024
- Revenue -23.74%
(FY 2023)
- Profit -209.22%
(FY 2023)
- Ebitda -116.61%
(FY 2023)
- Net Worth -5.72%
(FY 2023)
- Total Assets -9.04%
(FY 2023)
About Baxter Pharmaceuticals India
The Corporate was formerly known as Claris Lifesciences International Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2,000.00 Cr and a paid-up capital of Rs 0.57 M.
The company currently has active open charges totaling ₹5.00 Cr. The company has closed loans amounting to ₹1,130.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rishikesh Jaiwant, Tabish Zubair, Sanju Dhawan, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2005PTC046211
- Company No.
046211
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Baxter Pharmaceuticals India?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tabish Zubair  | Director | 09-Jul-2021 | Current |
| Sanju Dhawan | Director | 09-Jul-2021 | Current |
| Rishikesh Jaiwant | Director | 10-Jan-2019 | Current |
| Rahul Tambi | Director | 22-Jul-2022 | Current |
Financial Performance and Corporate Structure Insights of Baxter Pharmaceuticals India.
Baxter Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.74% decrease. The company also saw a substantial fall in profitability, with a 209.22% decrease in profit. The company's net worth dipped by a decrease of 5.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Baxter Pharmaceuticals India?
In 2023, Baxter Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 16 Jul 2019 | ₹5.00 Cr | Open |
Others Creation Date: 29 Mar 2016 | ₹1.18 M | Satisfied |
Others Creation Date: 19 Sep 2015 | ₹0.70 M | Satisfied |
How Many Employees Work at Baxter Pharmaceuticals India?
Baxter Pharmaceuticals India has a workforce of 1161 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Baxter Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Baxter Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
